Argenica Therapeutics Limited announced that last week the first subject was dosed in its Phase 1 clinical trial of ARG-007 in healthy volunteers. Importantly, the first dosed subject has shown no serious safety issues 24 hours after dosing and therefore dosing of the remaining participants in cohort one will be completed over the next three days. Following the dosing of these participants, all follow up data will be presented to the Scientific Review Committee who will then confirm the progress of the trial to the next cohort.

The Phase 1 clinical trial, conducted at Linear Clinical Research facility in Perth, Western Australia, will assess the safety and tolerability of ARG-007 across four cohorts of healthy adult volunteers, with each cohort receiving an ascending dose of ARG-007. The first volunteer dosed in each cohort is a sentinel subject, meaning this single volunteer receives the investigational drug at least 24 hours prior to the remaining subjects in the dose cohort. A second volunteer receives a placebo injection of saline at the same time as the sentinel subject.

The intention of the sentinel is to identify any unpredicted serious safety issues related to drug dosing in a single subject prior to exposing a larger group of subjects.